Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
6
2
2022
medline:
5
4
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
Oxcarbazepine as an anticonvulsant has been suggested as an effective drug in affective disorders. The present study was designed to compare the efficacy of oxcarbazepine and sodium valproate in the treatment of acute mania in the Iranian population. In a double-blind, randomized clinical trial, hospitalized bipolar patients in the acute manic phase who were admitted to Ibn-e-Sina psychiatric hospital in Mashhad city (north-eastern part of Iran) were enrolled. The diagnosis was confirmed using Structured Clinical Interview for DSM-IV-TR. Patients were then randomly allocated into two groups taking oxcarbazepine (900-2400 mg/day) and sodium valproate (about 20 mg/kg/day) for 6 weeks. Young Mania Rating Scale (YMRS), Clinical Global Impression Scale (CGI-S), and adverse effects of drugs were assessed at baseline and after 3 and 6 weeks. Mania symptoms based on mean scores of YMRS and CGI-S significantly decreased from baseline to endpoint in both treatments (P < 0.01). However, there was no significant difference between the two groups in terms of reduction of symptoms during times (P = 0.715 and P = 0.446, respectively) and adverse events (P > 0.05). This study confirmed the previous findings that indicate the efficacy of oxcarbazepine as same as sodium valproate. Moreover, its adverse effects resemble sodium valproate in the treatment of acutely manic patients.
Identifiants
pubmed: 35121700
doi: 10.1097/YIC.0000000000000394
pii: 00004850-202205000-00008
doi:
Substances chimiques
Valproic Acid
614OI1Z5WI
Oxcarbazepine
VZI5B1W380
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-121Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Akhondzadeh S, Mohajari H, Reza Mohammadi M, Amini H (2003). Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. BMC Psychiatry. 3:7.
Busner J, Targum SD (2007). The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont (Pa.: Township)). 4: 28–37.
Emrich H (1990). Studies with oxcarbazepine (TrileptalR) in acute mania. Int Clin Psychopharmacol. 5 (Suppl 1):83–88.
Emrich HM, Altmann H, Dose M, von Zerssen D (1983). Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav. 19:369–372.
Emrich HM, Dose M, von Zerssen D (1985). The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord. 8:243–250.
Gitlin M, Frye MA (2012). Maintenance therapies in bipolar disorders. Bipolar Disord. 14 (Suppl 2):51–65.
Hellewell JS (2002). Oxcarbazepine (trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord. 72 (Suppl 1):S23–S34.
Jochim J, Rifkin-Zybutz RP, Geddes J, Cipriani A (2019). Valproate for acute mania. Cochrane Database Syst Rev. 10:CD004052.
Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra D, Kataria D (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry. 24:178–182.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 334:1–100.
Maiti R, Mishra BR, Jowhar J, Mohapatra D, Parida S, Bisoi D (2017). Effect of oxcarbazepine on serum brain derived neurotrophic factor in bipolar mania: an exploratory study. Clin Psychopharmacol Neurosci. 15:170–176.
Muller A, Stoll K (1984). Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, editor. Anticonvulsants in affective disorders. Excerpta Medica. 139–147.
Murru A, Popovic D, Pacchiarotti I, Hidalgo D, León-Caballero J, Vieta E (2015). Management of adverse effects of mood stabilizers. Curr Psychiatry Rep. 17:603.
Nieto E (2008). Oxcarbazepina en el trastorno bipolar y trastornos esquizoafectivos. Actas Espanolas de Psiquiatria. 36 (Suppl 3):28–38.
Oulis P, Karapoulios E, Kouzoupis AV, Masdrakis VG, Kontoangelos KA, Makrilakis K, et al. (2007). Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report. Ann Gen Psychiatry. 6:25.
Popova E, Leighton C, Bernabarre A, Bernardo M, Vieta E (2007). Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother. 7:617–626.
Post R (2000). Mood disorders: treatment of bipolar disorders. Comprehensive textbook of psychiatry. Lippincott Williams & Wilkins.
Pratoomsri W, Yatham LN, Bond DJ, Lam RW, Sohn CH (2006). Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry. 51:540–545.
Raja M, Azzoni A (2003). Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. Int J Neuropsychopharmacol. 6:409–414.
Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, et al. (2013). A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol. 16, 485–496.
Reinstein MJ, Sonnenberg JG, Hedberg TG, Jones LE, Reyngold P (2003). Oxcarbazepine versus divalproex sodium for the continuing treatment of mania. Clin Drug Investig. 23:671–677.
Rowland TA, Marwaha S (2018). Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 8:251–269.
Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W (1997). Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73:159–171.
Suppes T, Kelly DI, Hynan LS, Snow DE, Sureddi S, Foster B, Curley E (2007). Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder. Aust N Z J Psychiatry. 41:397–402.
Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al. (2006). A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 163:1179–1186.
White HS (2003). Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 64 (Suppl 8):5–8.
Yatham LN (2004). Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry. 65, 28–35.
Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 133:429–435.